Genomic Health, Inc.
) reported the outcome of a significant study which confirmed that
the Oncotype DX test results for Recurrence Score and quantitative
estrogen-receptor (ER) can predict distant recurrence risk in
patients with early-stage breast cancer, after initial tamoxifen
Data from the study suggests that Oncotype DX may help identify
those patients who have higher chances to benefit from extended
hormonal treatment beyond five years. These results belong to one
of the nine Oncotype DX studies being presented at the 2014
American Society of Clinical Oncology (ASCO) Annual Meeting in
As per ASCO's guideline update, recent studies have revealed that
extending tamoxifen treatment for 10 years is associated with
better outcomes. However, better tools are required to identify
Further, this study confirmed that Oncotype DX can also help in
identifying patients who are at a lower risk for late recurrences
and will likely have less absolute benefit from extended tamoxifen.
As a result, this identification spares low-risk patients from
prolonged exposure to the treatment and the risk of long-term side
This new study analyzed 668 and 1065 patients from the original
NSABP (National Surgical Adjuvant Breast and Bowel Project) B-14
and B-28 trials, respectively. Results suggest that extending
tamoxifen therapy beyond 5 years may be particularly beneficial in
patients with high and intermediate Recurrence Scores, whose tumors
had higher quantitative estrogen receptor expression.
This fresh set of findings have accentuated Genomic Health's
ability to better guide a patient through his/her battle against
the deadly disease, by helping him/her take the most suitable and
best-informed breast cancer treatment decision.
Genomic Health currently has a Zacks Rank #3 (Hold). Some
better-ranked stocks worth considering in the biomedical industry
ANI Pharmaceuticals, Inc.
Myriad Genetics Inc.
). All these stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
ILLUMINA INC (ILMN): Free Stock Analysis Report
MYRIAD GENETICS (MYGN): Free Stock Analysis
GENOMIC HEALTH (GHDX): Free Stock Analysis
ANI PHARMACEUT (ANIP): Free Stock Analysis
To read this article on Zacks.com click here.